Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Maha Hussain, Stephanie Daignault, Przemyslaw Twardowski, Costantine Albany, Mark N. Stein, Lakshmi Priya Kunju, Dan R. Robinson, Kathleen A. Cooney, Robert B. Montgomery, Emmanuel S. Antonarakis, Daniel H. Shevrin, Paul Gettys Corn, Young E. Whang, David C. Smith, Megan Veresh Caram, Scott A. Tomlins, Karen E. Knudsen, Walter Michael Stadler, Felix Yi-Chung Feng, Arul M. Chinnaiyan
Institutions: Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Michigan, City Of Hope National Medical Center, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Rutgers Cancer Institute, Michigan Medicine, University of Utah, University of Washington, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Endeavor Health, The University of Texas MD Anderson Cancer Center, University of North Carolina at Chapel Hill, U-M Rogel Cancer Center, Thomas Jefferson University, Sidney Kimmel Cancer Center, University of Chicago, University of California, San Francisco
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2767139261